Pardeep S Jhund1, Inder S Anand2, Michel Komajda3, Brian L Claggett4, Robert S McKelvie5, Michael R Zile6, Peter E Carson7, John J V McMurray1. 1. BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. 2. Veterans Affairs Medical Center and University of Minnesota, Minneapolis, MN, USA. 3. Université Paris 6 and Hospital Pitié-Salpêtrière, Paris, France. 4. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. 5. Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada. 6. Ralph H. Johnson Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, SC, USA. 7. Georgetown University and Washington DC Veterans Affairs Medical Center, Washington, DC, USA.
Abstract
AIMS: In patients with heart failure (HF) and reduced ejection fraction, decreases or increases in NT-proBNP levels are associated with better and worse outcomes, respectively. The association in HF and preserved ejection fraction (HF-PEF) is unknown. We examined the association between change in level of NT-proBNP and prognosis in patients with HF-PEF. METHODS AND RESULTS: We examined the association between change in NT-proBNP from baseline to 6 months and cardiovascular (CV) death or HF hospitalization in 2612 participants in the Irbesartan in Patients with Heart Failure and Preserved Systolic Function Study (I-Preserve). Change in NT-proBNP was modelled as a restricted cubic spline in a Cox model after adjusting for baseline NT-proBNP and known prognostic variables. Median change in NT-proBNP from baseline was -7 pg/mL (interquartile range -143 to +108). After adjustment, a 1000 pg/mL decrease in NT-proBNP from baseline was associated with a reduction in the risk of CV death or HF hospitalization [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.53-1.02]; a 1000 pg/mL increase was associated with an increase in risk (HR 2.01, 95% CI 1.50-2.69). Beyond a 1000 pg/mL rise or fall, there was little additional change in risk. Addition of change in NT-proBNP at 6 months to a model with only baseline NT-proBNP improved the C-statistic from 0.752 to 0.769 (P = 0.013). CONCLUSION: In HF-PEF, a rise in NT-proBNP was associated with an increase in risk of CV death or HF hospitalization and a fall was associated with a trend towards a decrease in risk. NT-proBNP may be a useful marker to monitor prognosis in this condition.
AIMS: In patients with heart failure (HF) and reduced ejection fraction, decreases or increases in NT-proBNP levels are associated with better and worse outcomes, respectively. The association in HF and preserved ejection fraction (HF-PEF) is unknown. We examined the association between change in level of NT-proBNP and prognosis in patients with HF-PEF. METHODS AND RESULTS: We examined the association between change in NT-proBNP from baseline to 6 months and cardiovascular (CV) death or HF hospitalization in 2612 participants in the Irbesartan in Patients with Heart Failure and Preserved Systolic Function Study (I-Preserve). Change in NT-proBNP was modelled as a restricted cubic spline in a Cox model after adjusting for baseline NT-proBNP and known prognostic variables. Median change in NT-proBNP from baseline was -7 pg/mL (interquartile range -143 to +108). After adjustment, a 1000 pg/mL decrease in NT-proBNP from baseline was associated with a reduction in the risk of CV death or HF hospitalization [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.53-1.02]; a 1000 pg/mL increase was associated with an increase in risk (HR 2.01, 95% CI 1.50-2.69). Beyond a 1000 pg/mL rise or fall, there was little additional change in risk. Addition of change in NT-proBNP at 6 months to a model with only baseline NT-proBNP improved the C-statistic from 0.752 to 0.769 (P = 0.013). CONCLUSION: In HF-PEF, a rise in NT-proBNP was associated with an increase in risk of CV death or HF hospitalization and a fall was associated with a trend towards a decrease in risk. NT-proBNP may be a useful marker to monitor prognosis in this condition.
Authors: Mohammad R Ostovaneh; Kasra Moazzami; Kihei Yoneyama; Bharath A Venkatesh; Susan R Heckbert; Colin O Wu; Steven Shea; Wendy S Post; Annette L Fitzpatrick; Gregory L Burke; Hossein Bahrami; Otto A Sanchez; Lori B Daniels; Erin D Michos; David A Bluemke; João A C Lima Journal: Hypertension Date: 2019-12-23 Impact factor: 10.190
Authors: Leah Rethy; Barry A Borlaug; Margaret M Redfield; Jae K Oh; Sanjiv J Shah; Ravi B Patel Journal: J Am Soc Echocardiogr Date: 2021-01-21 Impact factor: 5.251
Authors: Vinithra Varadarajan; Bharath Ambale-Venkatesh; Seo Young Hong; Mohammadali Habibi; Hiroshi Ashikaga; Colin O Wu; Lin Y Chen; Susan R Heckbert; David A Bluemke; Joao A C Lima Journal: Am J Hypertens Date: 2021-06-22 Impact factor: 3.080
Authors: Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani Journal: Cochrane Database Syst Rev Date: 2020-02-27
Authors: Wei Yang; Yu Jie Zhou; Yan Fu; Jian Qin; Shu Qin; Xiao Min Chen; Jin Cheng Guo; De Zhao Wang; Hong Zhan; Jing Li; Jing Yu He; Qi Hua Journal: Yonsei Med J Date: 2017-01 Impact factor: 2.759